Luxottica (LUXTY-5) Stock Predictions - Stockchase
WATCH LIST
40
Luxottica (LUXTY-5)

ON STOCKCHASE SINCE Feb 2001

Owns Lenscrafters stores plus manufactures Ray Bans, etc. Owns US's largest vision care provider.

Delisted June 2017

biotechnology/pharmaceutical

Luxottica

LUXTY-5

2 watching          
Join the Discussion

Luxottica (LUXTY-5) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about LUXTY-5



  • All
  • Filtered
Signal Opinion Expert
HOLD
Luxottica(LUXTY-5) 

March 2, 2018

This company is a good one, but sunglasses are a discretionary item.  Now is not the time to initiate a position – if you own it, hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This company is a good one, but sunglasses are a discretionary item.  Now is not the time to initiate a position – if you own it, hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Thomas George

, TD Asset Management...

Price Price
$60.900
Owned Owned
No

DON'T BUY
Luxottica(LUXTY-5) 

February 21, 2018

This company makes eyewear and owns Lenscrafters.    He is not a big fan of a company that owns both lens manufacturing and eyewear as they are viewed as competitors by other eyewear manufacturers.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This company makes eyewear and owns Lenscrafters.    He is not a big fan of a company that owns both lens manufacturing and eyewear as they are viewed as competitors by other eyewear manufacturers.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$60.900
Owned Owned
No

COMMENT
Luxottica(LUXTY-5) 

December 28, 2017

Has merged with Essilor (EI-FP), and is just waiting for EU approval. If interested in Luxottica, you should think of Essilor instead. This merger will give you a gargantuan conglomerate that will dominate pricing. Essilor is not just eyeglasses, 2/3 of Chinese are myopic and in need of reading glasses. With the aging population there is still good opportunity in Essilor moving forward. Dividend growth has been roughly 15% a year, double what the growth rate is on average.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has merged with Essilor (EI-FP), and is just waiting for EU approval. If interested in Luxottica, you should think of Essilor instead. This merger will give you a gargantuan conglomerate that will dominate pricing. Essilor is not just eyeglasses, 2/3 of Chinese are myopic and in need of reading glasses. With the aging population there is still good opportunity in Essilor moving forward. Dividend growth has been roughly 15% a year, double what the growth rate is on average.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$60.900
Owned Owned
Yes

COMMENT
Luxottica(LUXTY-5) 

November 21, 2017

Merging with Essilor (EI-FP), the leading lens producer, and a lot of people view this as very positive, but isn’t sure he feels the same. Luxottica is the parent of LensCrafters, and he wonders why they would do business with their competitor. Prefers Hoya Corp (7741-JP).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Merging with Essilor (EI-FP), the leading lens producer, and a lot of people view this as very positive, but isn’t sure he feels the same. Luxottica is the parent of LensCrafters, and he wonders why they would do business with their competitor. Prefers Hoya Corp (7741-JP).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$60.900
Owned Owned
Unknown

DON'T BUY
Luxottica(LUXTY-5) 

March 27, 2017

He prefers another in the vision space.  He likes the vision space, though.  There is aging going on in the world.  The use of computer screens has lead to more needs for vision correction. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He prefers another in the vision space.  He likes the vision space, though.  There is aging going on in the world.  The use of computer screens has lead to more needs for vision correction. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$55.600
Owned Owned
No

COMMENT
Luxottica(LUXTY-5) 

August 25, 2016

He is positive on this name because of the moats, the amount of capital you would have to create, to take the company on. They’ve been hurt because they’ve had a big expansion on their PE multiple up to 30X, and has come back down again because it is not growing as fast as the analysts want them to. They have very little competition and they are in e-commerce.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He is positive on this name because of the moats, the amount of capital you would have to create, to take the company on. They’ve been hurt because they’ve had a big expansion on their PE multiple up to 30X, and has come back down again because it is not growing as fast as the analysts want them to. They have very little competition and they are in e-commerce.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$48.550
Owned Owned
Yes

COMMENT
Luxottica(LUXTY-5) 

August 2, 2016

Had no idea how dominant their position was, not just in retail eyewear in terms of exclusive retail rights for a lot of brands, but also owning the optical retail locations as well. This is as close to a monopoly as you can be. A phenomenal business and the returns are great. When you have businesses that have to make transitions from the individual to a corporation, you can run into a lot of problems. Great business, but when the management team changed he stopped following it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had no idea how dominant their position was, not just in retail eyewear in terms of exclusive retail rights for a lot of brands, but also owning the optical retail locations as well. This is as close to a monopoly as you can be. A phenomenal business and the returns are great. When you have businesses that have to make transitions from the individual to a corporation, you can run into a lot of problems. Great business, but when the management team changed he stopped following it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Greg Dean

Principal , Cambridge Global Ass...

Price Price
$47.710
Owned Owned
No

TOP PICK
Luxottica(LUXTY-5) 

December 9, 2015

We know this through the 6500 retail stores including Sunglass Hut and LensCrafters. They also have the brand names of Ray-Ban and others. Also, they are the exclusive licensed supplier and distributor of Google Glass, and have just signed a deal with Intel to do work on smart glasses with Oakley. Underneath all of that there is a demographic wave of us getting older and needing glasses. A beautiful name and low volatility. Dividend yield of 1.2%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

We know this through the 6500 retail stores including Sunglass Hut and LensCrafters. They also have the brand names of Ray-Ban and others. Also, they are the exclusive licensed supplier and distributor of Google Glass, and have just signed a deal with Intel to do work on smart glasses with Oakley. Underneath all of that there is a demographic wave of us getting older and needing glasses. A beautiful name and low volatility. Dividend yield of 1.2%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$66.610
Owned Owned
Yes

BUY
Luxottica(LUXTY-5) 

May 30, 2012

Domiciled in Italy. Facilitating company. Higher end sunglasses. Margin might be difficult to create. 75% of revenue from US. He would add it for new clients.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Domiciled in Italy. Facilitating company. Higher end sunglasses. Margin might be difficult to create. 75% of revenue from US. He would add it for new clients.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Karl Berger

Partner, Toron Investment Man...

Price Price
$32.530
Owned Owned
Yes

BUY
Luxottica(LUXTY-5) 

February 2, 2012

Integrated eyeglass company. Manufacture for a whole host of brands, some of which they wholly own. They also retail. Well-run company. Gets far more of its revenue from the US than it does from Europe. Should be able to grow its earnings at high single-digit/low double-digit for many years to come.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Integrated eyeglass company. Manufacture for a whole host of brands, some of which they wholly own. They also retail. Well-run company. Gets far more of its revenue from the US than it does from Europe. Should be able to grow its earnings at high single-digit/low double-digit for many years to come.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Charles Lannon

Director o, Toron Investment Man...

Price Price
$33.250
Owned Owned
Yes

TOP PICK
Luxottica(LUXTY-5) 

January 20, 2012

Sunglasses. Italian domiciled company and get about 25% of revenues from European operations and the rest from outside of Europe. Have done fairly well through recessionary times. If spending gets back up to luxury levels, they should do even better.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Sunglasses. Italian domiciled company and get about 25% of revenues from European operations and the rest from outside of Europe. Have done fairly well through recessionary times. If spending gets back up to luxury levels, they should do even better.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Karl Berger

Partner, Toron Investment Man...

Price Price
$30.830
Owned Owned
Yes

COMMENT
Luxottica(LUXTY-5) 

April 7, 2010

Dominate eyeglasses/sunglasses sector. Their competition is very fragmented globally. Growth in China and other emerging markets is going to grow over time. Just moved into South America. Stock is a little rich right now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Dominate eyeglasses/sunglasses sector. Their competition is very fragmented globally. Growth in China and other emerging markets is going to grow over time. Just moved into South America. Stock is a little rich right now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$26.790
Owned Owned
Yes

COMMENT
Luxottica(LUXTY-5) 

March 20, 2009

People still need glasses, usually every 2 years. Sales were down and margins have declined. Suspended the dividend because they want to pay down some debt from their Oakley acquisition. Oakley is going great guns, as is the lower end of their business. As the economy turns around, they will start to improve.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
People still need glasses, usually every 2 years. Sales were down and margins have declined. Suspended the dividend because they want to pay down some debt from their Oakley acquisition. Oakley is going great guns, as is the lower end of their business. As the economy turns around, they will start to improve.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$13.930
Owned Owned
Yes

PAST TOP PICK
Luxottica(LUXTY-5) 

December 12, 2008

(A Top Pick Dec 6/07. Down 42%.) Designer glasses. Discretionary consumer products will have a negative impact during recessions. Still likes. Would buy more if it got cheaper. 3.5% yield. Getting into China in a big way.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Dec 6/07. Down 42%.) Designer glasses. Discretionary consumer products will have a negative impact during recessions. Still likes. Would buy more if it got cheaper. 3.5% yield. Getting into China in a big way.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$19.020
Owned Owned
Yes

BUY
Luxottica(LUXTY-5) 

August 11, 2008

Chance to dollar cost average. Will expand retail stores in China (up to 1000 stores) in next 3 years. Still growing 15-20% range despite economy slowing down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chance to dollar cost average. Will expand retail stores in China (up to 1000 stores) in next 3 years. Still growing 15-20% range despite economy slowing down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$27.060
Owned Owned
Yes

Showing 1 to 15 of 40 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days